Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?
More details
Hide details
Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Katedra i Klinika Gastroenterologii i Hepatologii, Wydział Lekarski w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach
Oddział Chirurgii Ogólnej i Endokrynologicznej, Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Wielospecjalistyczny w Jaworznie
Corresponding author
Marek Waluga   

Marek Waluga, Katedra i Klinika Gastroenterologii i Hepatologii, Wydział Lekarski w Katowicach, Śląskiego Uniwersytetu Medycznego w Katowicach, ul. Medyków 14, 40-752 Katowice, tel. +48 32 789 44 01
Ann. Acad. Med. Siles. 2015;69:91-98
The combined therapy of pegylated alpha interferon and rybavirin is a gold standard of chronic viral hepatitis C (cvhC) treatment.

The aim of the study is to evaluate the laboratory test differences between the group of cvhC patients which achieved and did not achieve sustained virologic response (SVR).

Materials and methods:
51 patients (25 women, 26 men, age 48.7 ± 12.8 years) were divided into two groups depending on SVR achievement. SVR was achieved in 41.2% of patients [(SVR(+)]. The concentration of hemoglobin, hematocrite, the number of erythrocytes, leucocytes, platelets, glucose, bilirubin, creatinin, uric acid, fT3, fT4, TSH, C-reactive protein (CRP), the activity of asparaginian and alaninian transaminases, alkaline phosphatase, gammaglutamylotranspeptidase, were estimated before the start of treatment and after 12, 24, 48 and 72 weeks after beginning it. Statistic analysis was performed by ANOVA of Friedmann, U Mann-Withney and t-Student tests.

The activity of AspAT, AlAT in the SVR(+) group was lower from the 12th week until the 72nd week of observation. GGTP activity was statistically significant lower in the SVR(+)group. The decrease in TSH concentration in the 12th week and the increase in fT4 concentration in week 24 was clearer in the SVR(+) group. The hematocrite was lower in the SVR(+) group in the 48th week from the beginning of therapy and 24 weeks after the end of it.

Patients treated with pegylated interferon α2a and rybavirine due to cvhC rarely achieve SVR if the GGTP activity is higher before the treatment and if the aminotranferases activity is higher during therapy. Latent hyperthyreosis can be a good predictive factor.

Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29(suppl 1): 74–81.
Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006; 45: 529–538.
Zeuzem S., Berg T., Moeller B. i wsp. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral. Hepat. 2009; 16: 75–90.
Ghany M.G., Strader D.B., Thomas D.L. i wsp. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.
Manns M.P., McHutchison J.G., Gordon S.C. i wsp. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
Fried M.W., Shiffman M.L., Reddy K.R. i wsp. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975–982.
Abbasi A., Bhutto A.R., Butt N., Munir S.M. Efficacy of interferon-ribavirin therapy in chronic hepatitis C patients. J. Coll. Physicians. Surg. Pak. 2011; 21: 276–279.
Sung H., Chang M., Saab S. Management of hepatitis C antiviral therapy adverse effects. Curr. Hepatitis. Rep. 2011; 10: 33–40.
Russo M.W., Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711–1719.
Foster G.R. Quality of life considerations for patients with chronic hepatitis C. J. Viral. Hepat. 2009; 16: 605–611.
Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002 Nov; 36 (5 Suppl 1): S237–244.
Chak E., Saab S. Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response. Curr. Hepat. Rep. 2010; 9: 147–154.
McHutchinson J.G., Manns M., Patel K. i wsp. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
Reddy K.R., Nelson D.R., Zeusem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol. 2009; 50: 402–411.
Izumi N., Asahina Y., Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat. Res. Treat. 2010; 2010:703602.
Yamada G., Iino S., Okuno T. i wsp. Virological response in patients with hepatitis C virus genotype 1b and a high vidal load: impact of peginterferon-α-2a plus ribavirin dose reductions and host-related factors. Clin. Drug. Invest. 2008; 28: 9–16.
Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241–246.
Kleiner D.E., Brunt E.M., Van Natta M. i wsp. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 1991; 13: 372–374.
Soza A., Everhart J.E., Ghany M.G. i wsp. Neutropenia turing combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273–1279.
Loustaud-Ratti V., Carrier P., Rousseau A. i wsp. Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig. Liver. Dis. 2011; 43: 850–855.
Sievert W., Dore G.J., McCaughan G.W. i wsp. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53: 1109–1117.
Butt A.A., Umbleja T., Andersen J.W. i wsp. The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment. Pharmacol. Ther. 2011; 33: 1234–1244.
Shirakawa H., Matsumoto A., Joshita S. i wsp. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753–1760.
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Int. Med. 2004; 140: 370–381.
Nagayama K., Enomoto N., Izumi N. i wsp. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 2001; 48: 830–835.
Aoki YH., Ohkoshi S., Yamagiwa S. i wsp. Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol. Res. 2011; 41: 118–125.
Amanzada A., Goralczyk A.D., Schneider S. i wsp. High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study. Digestion 2012; 86: 218–27. doi: 10.1159/000339879. Epub 2012 Sep 5.
Tarantino G., Conca P., Sorrentino P. i wsp. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J. Gastroenterol. Hepatol. 2006; 21: 1266–1268.
Charlton M.R., Pockros P.J., Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177–1186.
Walsh M.J., Jonsson J.R., Richardson M.M. i wsp. Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529–535.
Romero-Gomez M. Insulin resistance and Hepatitis C. World J. Gastroenterol. 2006; 12: 7075–7080.
Romero-Gomez M., Del Mar Viloria M., Andrade R.J. i wsp. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.
Poustchi H., Negro F., Hui J. i wsp. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Hepatol. 2008; 48: 28–34.
Eslam M., Aparcero R., Romero-Gomez M. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Ann. Hepatol. 2011; 10: 241–243.
Tran H.A., Reeves G.E.M., Gibson R. i wsp. Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virologic response: A meta-analysis. J. Gastroenterol. Hepatol. 2009; 24: 1163–1168.
Tran H.A., Reeves G.E.M., Jones T.L. The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohorte of patients with chronic hepatitis C infection. QJM, 2009; 102: 117–122.
Journals System - logo
Scroll to top